GI Dynamics to Hold Briefing Call and Webcast on
Financial Results for First Quarter 2014
EndoBarrier® Therapy Receives Reimbursement Coverage in Israel
GI Dynamics Expands Availability of EndoBarrier® Therapy in Australia in Two Additional Cities
EndoBarrier® is indicated to treat patients with type 2 diabetes and/or obesity for 12 months.
EndoBarrier® has received regulatory approval and is commercially available for use in select international markets.
EndoBarrier® is not approved for sale in the United States and is considered investigational.
CAUTION: INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL (UNITED STATES) LAW TO INVESTIGATIONAL USE